Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Integrative Prognostic Value of Inflammatory Markers and KELIM Score in Ovarian Cancer Patients Treated With Neoadjuvant Chemotherapy.

NCT07678008 is registered in ClinicalTrials.gov with Aya Ahmed Nasser as lead sponsor.

NCT NCT07678008
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07678008 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Integrative Prognostic Value of Inflammatory Markers and KELIM Score in Ovarian Cancer Patients Treated With Neoadjuvant Chemotherapy.
Lead sponsor
Aya Ahmed Nasser
Phase
Observational
Overall status
Active, not recruiting
Start date
June 1, 2026
Completion date
February 1, 2027
Enrollment
80 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

advanced ovarian cancer (stage iii or iv) after neoadjuvant chemotherapy, high-grade serous ovarian carcinoma